Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic commercial supply agreement with CarThera® for the use of Lantheus’ microbubbles in combination with SonoCloud®, a proprietary implantable device in development for the treatment of recurrent glioblastoma (rGBM). Gliobastoma is a lethal and devastating form of brain cancer with median survival of 15 months after diagnosis1. The collaboration directly aligns with key Lantheus growth strategies of pursuing new applications for its microbubble franchise and expansion into oncology.

Under the commercial supply agreement, Lantheus’ microbubbles will be used as a component in CarThera’s SonoCloud® System, which uses low-intensity pulsed ultrasound (LIPU) specifically designed to open the blood-brain barrier to facilitate more effective delivery of chemotherapy to tumors. As part of the agreement, CarThera will be responsible for regulatory filings and approvals in the U.S., Europe and rest of world as well as commercialization of SonoCloud®. Lantheus will supply its microbubble vials (the ultrasound resonator) and activation devices at a predetermined transfer price. Additionally, Lantheus will receive royalties on the SonoCloud® kit product sales upon regulatory approval.

“We are excited to collaborate with CarThera to extend our microbubble franchise into the oncology field to target glioblastoma, an aggressive type of brain cancer with significant unmet medical need,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. “Our collaboration leverages both companies’ strengths to bring novel solutions to the healthcare community. As the use of microbubbles in diagnostic and therapeutic applications gains more interest around the world, our collaboration with CarThera demonstrates our commitment to drive Lantheus’ microbubble into new disease areas with great potential for significant improvement in patient outcomes.”

“We are delighted to enter into this collaboration with Lantheus for the development of our SonoCloud ultrasound-based medical device,” said Frederic Sottilini, Chief Executive Officer of CarThera. “With Lantheus’ expertise in the field of microbubbles combined with CarThera’s novel and proprietary ultrasound technology, we see the potential for a long-term, highly successful collaboration. We are excited to work with Lantheus to advance our promising SonoCloud technology with the goal of improving treatment and prognosis of patients with glioblastoma, a debilitating, and all too often, fatal disease.”

CarThera’s SonoCloud-9 System is currently being evaluated in a Phase IIa clinical trial with a Phase IIb/III pivotal clinical trial to follow. The objective of this trial to evaluate the safety and efficacy of repeated opening of the blood brain barrier using the SonoCloud-9, its next-generation implantable ultrasound device designed to cover the entire tumor and surrounding infiltrative areas. Twenty-one patients will undergo repeated blood brain barrier opening with the SonoCloud-9 prior to infusion of carboplatin at clinical sites in France (Paris, Lyon, Marseille, Angers) and the United-States (MD Anderson Cancer Center in Houston, Northwestern Memorial Hospital in Chicago).

Source: Company Press Release